Kemp Dolliver: That’s very helpful. Thank you. And how are you thinking about the prioritization depending on €“ and again, we are in an environment where the incremental dollars have been harder to get and you may get all the capital you need quickly or it may be a challenge. But is it fair to assume that fadra going into Phase 2, if you had to focus on one priority initially that’s where you would direct the capital?
Spiro Rombotis: Yes. Well, we live obviously, in risk mitigation across all programs, but you are correct. In that situation, we just portrayed fadra, the 101 study in solid tumors and lymphoma is the number one priority. And we intend to report early readouts on that study this year as we think this is critical to strategic parties that are approaching the company to discuss interest in this program. And there are two reasons for that, in my opinion. One is that this has been a field of great interest to pharma for many years. As many of the audience know, there have been a large number of programs in the next-generation CDK family. Fadra is one of the leading, if not the leading program in this area. So, it has obviously been on the radar of many companies.
The second reason is the scarcity value of this drug. I think that as we learned from ASH and earlier on other conferences of 2022, fadra is so far the only drug in the next-generation CDK family to have single-agent activity and a good tolerability profile, especially if we think about the unmet medical needs in lymphomas, in particular T-cell lymphoma and endometrial, ovarian and other women’s cancers. I think it’s clear to see why, for us, this remains by far the biggest value driver for the company in the year going forward.
Kemp Dolliver: Very helpful. Thank you.
Spiro Rombotis: Thank you, Kemp.
Operator: And it does appear that we have no further questions at this time. I am happy to return the call to our host for any concluding remarks.
Spiro Rombotis: Thank you, operator and thanks to all of you for joining Cyclacel’s fourth quarter and full year earnings call. The key takeaway from today’s call is that, as momentum builds with our two clinical programs, their potential of becoming important anticancer therapeutics in solid tumors and lymphoma is becoming apparent in both medical and industry circles. As a reminder, our key milestones for 2023 are. Report final data from dose escalation stage and recommended Phase 2 dose determination from the 065-101 study of oral fadraciclib in patients with advanced solid tumors and lymphoma. First patient dosed with oral fadra in Phase 2 proof-of-concept stage of 065-101 study in patients with advanced solid tumors and lymphoma, PORT interim Phase 1 data from 140-101 study of oral plogosertib in patients with advanced solid tumors and lymphoma, PORT interim data from initial cohorts in Phase 2 proof-of-concept study of 065-101 with oral fadraciclib in patients with advanced solid tumors and lymphoma, PORT interim data from dose escalation stage of 065-102 study with oral fadraciclib in patients with advanced leukemia.
And report final data from dose escalation stage of 140-101 study with oral plogosertib in advanced solid tumor cell lymphoma. We look forward to providing you with further updates, and hope to meet some of you at upcoming conferences. Operator, at this time you may end the call.
Operator: This does conclude today’s conference. You may now disconnect your lines and everyone, have a great day.
